Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.

Current opinion in pharmacology - 1 Feb 2015

Scharf Sebastian H, Jaeschke Georg, Wettstein Joseph G, Lindemann Lothar

Abstract excerpt

Fragile X syndrome (FXS) is the most common monogenic form of inherited mental retardation caused by a trinucleotid repeat expansion and transcriptional shutdown of the FMR1 gene. FXS patients present a complex and often severe neuropsychiatric phenotype yet have mild somatic symptoms, normal life expectancies, and no indications of neurodegeneration. The therapeutic potential of mGlu5 inhibitors was proposed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Excitatory Amino Acid Antagonists
Share to Fragile X Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Indoles

Share to Mice, Knockout

Share to Molecular Targeted Therapy

Share to Pyridines

Share to Receptor, Metabotropic Glutamate 5

Source

Identifiers

PMID: 25488569
DOI: 10.1016/j.coph.2014.11.004

Genes

FMR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.PMID 25488569Read ↗

Advances in the treatment of fragile X syndrome.Semantic proximity Read ↗

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.Semantic proximity Read ↗

Correction of fragile X syndrome in mice.Semantic proximity Read ↗

Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.Semantic proximity Read ↗

Investigating potential treatment strategies and underlying mechanisms in the Fragile X Syndrome mouse and rat modelsSemantic proximity Read ↗

New perspectives on the biology of fragile X syndrome.Semantic proximity Read ↗

Advances in understanding fragile X syndrome and related disorders.Semantic proximity Read ↗

Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila.Semantic proximity Read ↗

Therapeutic implications of the mGluR theory of fragile X mental retardationSemantic proximity Read ↗

Clinical, molecular, and pharmacological aspects of FMR1 related disorders.Semantic proximity Read ↗

The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.Semantic proximity Read ↗

mGluR5 Negative Modulators for Fragile X: Resistance and PersistenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.